Advertisement
BIOA vs TKNO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Buy and TKNO is a Buy.
BIOA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BIOA turned positive on October 20, 2026. Looking at past instances where BIOA's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIOA's RSI Indicator exited the oversold zone, 4 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on BIOA as a result. In 33 of 40 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +8.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOA advanced for three days, in 98 of 121 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
BIOA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 21 of 24 cases where BIOA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for BIOA entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (6.379). P/E Ratio (-2.234) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (29.762) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BIOA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
TKNO's RSI Oscillator ascends from oversold territory
The RSI Oscillator for TKNO moved out of oversold territory on October 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TKNO as a result. In 69 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TKNO just turned positive on October 29, 2026. Looking at past instances where TKNO's MACD turned positive, the stock continued to rise in 43 of 46 cases over the following month. The odds of a continued upward trend are 90%.
TKNO moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TKNO crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +11.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where TKNO advanced for three days, in 226 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
TKNO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TKNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TKNO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.698) is normal, around the industry mean (6.379). P/E Ratio (-25.194) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (8.718) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TKNO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TKNO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
BIOA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 94 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 83 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BIOA | TKNO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| Declines ODDS (%) | 6 days ago 82% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIOA’s FA Score shows that 1 FA rating(s) are green while TKNO’s FA Score has 1 green FA rating(s).
- BIOA’s FA Score: 1 green, 4 red.
- TKNO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIOA’s TA Score shows that 5 TA indicator(s) are bullish while TKNO’s TA Score has 7 bullish TA indicator(s).
- BIOA’s TA Score: 5 bullish, 3 bearish.
- TKNO’s TA Score: 7 bullish, 3 bearish.
Price Growth
BIOA (@Pharmaceuticals: Generic) experienced а -3.02% price change this week, while TKNO (@Pharmaceuticals: Generic) price change was +18.94% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
TKNO is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
BIOA and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.
| Ticker / NAME | Correlation To BIOA | 1D Price Change % | ||
|---|---|---|---|---|
| BIOA | 100% | +1.58% | ||
| UPC - BIOA | 43% Loosely correlated | -3.13% | ||
| NBIX - BIOA | 38% Loosely correlated | +0.17% | ||
| TKNO - BIOA | 26% Poorly correlated | +2.11% | ||
| HROW - BIOA | 23% Poorly correlated | +10.52% | ||
| TEVA - BIOA | 23% Poorly correlated | -1.33% | ||
More | ||||
TKNO and
Correlation & Price change
A.I.dvisor tells us that TKNO and EBS have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TKNO and EBS's prices will move in lockstep.
| Ticker / NAME | Correlation To TKNO | 1D Price Change % | ||
|---|---|---|---|---|
| TKNO | 100% | +2.11% | ||
| EBS - TKNO | 27% Poorly correlated | -0.82% | ||
| SNDL - TKNO | 26% Poorly correlated | -0.71% | ||
| BIOA - TKNO | 25% Poorly correlated | +1.58% | ||
| CRON - TKNO | 25% Poorly correlated | -3.67% | ||
| SBFM - TKNO | 24% Poorly correlated | +3.64% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| STOCK / NAME | Price $ | Chg $ | Chg % |
| AXS | 107.96 | 1.46 | +1.37% |
| Axis Capital Holders Limited | |||
| TNSR.X | 0.024675 | 0.000067 | +0.27% |
| Tensor cryptocurrency | |||
| DSGR | 34.97 | 0.02 | +0.06% |
| Distribution Solutions Group | |||
| ZIL.X | 0.001606 | -0.000039 | -2.38% |
| Zilliqa cryptocurrency | |||
| PERP.X | 0.016209 | -0.000982 | -5.71% |
| Perpetual Protocol cryptocurrency | |||